2026

Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusionpositive NSCLC.
Rosnev, Stanislav, Klein, Katharina, Heukamp, Lukas, Lenk, Julian, Joosten, Maria, Möbs, Markus, Grob, Tobias, Benary, Manuela, Vecchione, Loredana, Ott, Claus-Eric, Modest, Dominik P., Knödler, Maren, Keller, Ulrich, Frost, Nikolaj, Keilholz, Ulrich, Kiewe, Philipp and Rieke, Damian T.
Oncologist : oyag151. 21 April 2026 (In Press)

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.
Rieke, Damian T., Schwartz, Stefan, Ochsenreither, Sebastian, Chapuy, Björn, Amthauer, Holger, Deubzer, Hedwig E., Lehmann, Annika, Keilholz, Ulrich, Wardelmann, Eva, Vokuhl, Christian, Eggert, Angelika, Fröhling, Stefan, Horst, David, Capper, David, Keller, Ulrich, Dragomir, Mihnea P. and Schallenberg, Simon
Oncologist 7 April 2026 (In Press)

2024

A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass.
Habringer, S., Ihlow, J., Kleo, K., Klostermann, A., Schmidt, M., Chai, L., Knödler, M., Leyvraz, S., Sigler, C., Sinn, B., Maschmeyer, G., Jegodka, Y., Benary, M., Ott, C.E., Tinhofer, I., Schäfer, R., Möbs, M., Keller, U., Keilholz, U. and Rieke, D.T.
Oncologist 29 (10): 908-912. October 2024